March 3, 2026Open Access

Bruceine D ameliorates cholestatic liver injury by selectively modulating bile acid synthesis and activating FXR–SHP signaling

Key Points

Bruceine D alleviates cholestatic liver injury through specific modulation of bile acid synthesis.
The treatment results in a less hepatotoxic bile acid profile and reduced inflammation and fibrosis.
Analysis shows restoration of FXR-dependent signaling as a key mechanism behind Bruceine D's effects.
This therapy could be a promising option for cholestatic liver diseases, but further validation is needed.

Abstract

BD ameliorates cholestatic liver injury by selectively inhibiting classical BA synthesis, quantitatively remodeling the BA pool toward a less hepatotoxic profile, and suppressing inflammation and fibrosis through functional restoration of FXR-dependent feedback signaling. Its synthesis-centered mechanism and favorable short-term safety profile support BD as a promising therapeutic candidate for cholestatic liver diseases.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Chuankui Fu

Ruihua Huang

Qingui Sun

Journals

Phytomedicine

Actions

Institutions

Central South University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Bruceine D ameliorates cholestatic liver injury by selectively modulating bile acid synthesis and activating FXR–SHP signaling

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider